# A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients

> **NCT03066804** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 2572 (actual)

## Conditions studied

- Heart Failure With Preserved Ejection Fraction

## Interventions

- **DRUG:** sacubitril/valsartan
- **DRUG:** Enalapril
- **DRUG:** Valsartan
- **DRUG:** Placebo to match sacubitril/valsartan
- **DRUG:** Placebo to match enalapril
- **DRUG:** Placebo to match valsartan

## Key facts

- **NCT ID:** NCT03066804
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-22
- **Primary completion:** 2019-10-28
- **Final completion:** 2019-10-28
- **Target enrollment:** 2572 (ACTUAL)
- **Last updated:** 2021-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03066804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03066804, "A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03066804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*